A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...
For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...
People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...
The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results